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BACKGROUND. Patients with small papillary thyroid carcinoma (PTC) may have a
high incidence of regional lymph-node (LN) metastases at presentation, and
these are considered to be an independent risk factor for tumor recurrence. A
mutated transketolase transcript (TKTL1) has been found up-regulated in differ-
ent human malignancies, and strong TKTL1 protein expression has been asso-
ciated with aggressiveness and poor patient survival in several epithelial cancers.
METHODS. TKTL1 protein expression was analyzed in 256 consecutive cases of
PTCs 1.5 cm by immunohistochemistry with a specific anti-TKTL1 antibody.
RNA analysis was performed by real-time polymerase chain reaction (PCR) in all
cases for which frozen material was available, which resulted in 55 fragments of
PTC.
RESULTS. Increased levels of TKTL1 transcript were detected in 50 of 55 analyzed
tumors compared with their corresponding normal tissues. Significant differences
in TKTL1 transcript levels were found between cases of PTC with and without LN
metastases. In primary tumors, immunoreactivity for TKTL1 was detected in the
majority of cases, ranging from 0% to 95.0% (mean, 50.11%  27.75%). A signifi-
cant association was found between TKTL1 protein expression and the presence
of multifocality, bilaterality, extrathyroidal extension, vascular invasion, sclerosis,
and LN metastases. In cases with LN metastases, a positive correlation was found
between the TKTL1 protein expression in primary tumors and the number of
metastatic LNs as well as the diameter of the largest metastatic area in LNs.
CONCLUSIONS. These findings suggest that TKTL1 overexpression in PTC 1.5 cm
may be considered a factor that facilitates tumor growth and progression. Cancer
2008;113:936–44.  2008 American Cancer Society.
KEYWORDS: papillary thyroid carcinoma (PTC), tranketolase-like-1 (TKTL1),
lymph-node metastases, pentose phosphate pathway (PPP), aerobic glycolysis.
P apillary thyroid carcinoma (PTC) is the most frequent thyroidcancer, accounting for 85% to 90% of all thyroid malignancies.
Improvement in diagnostic tools, such as ultrasonography, fine-
needle aspiration biopsy, and pathologic procedures allows the iden-
tification of a huge number of small cancers, which, in the majority
of cases, are PTCs associated with a good prognosis.1-4
Several studies have focused on thyroid cancers no larger than
1 cm in diameter (classified as microcarcinomas), but it is not
entirely clear whether 1.0-cm tumor size should be considered a
threshold for risk evaluation or whether carcinomas larger than 1.0
cm, but still small (no larger than 1.5 cm. in diameter), can also be
expected to have a similar favorable clinical behavior to that of
tumors no larger than 1.0 cm.2,3,5 Because they are often found in
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thyroid glands resected for other lesions, small PTCs
are often described as occult or incidental. Neverthe-
less, patients presenting with small PTCs may also
have a high incidence of regional lymph-node (LN)
metastases, which are the main route for the spread
of PTC cancer cells.6
Several reports suggest that presence of LN
metastases decreases cure rates and represents an in-
dependent risk factor for tumor recurrence.7-10 How-
ever, the clinical management of LN metastasis,
including the extent of initial surgery and the proper
indication for radioiodine therapy, is still controver-
sial.
During tumorigenesis, cells acquire genetic
alterations that are responsible for modifications in
their metabolism. Cancer cells characteristically pres-
ent increased glucose uptake that is metabolized by
anaerobic degradation, which leads to production of
large amounts of lactate even in the presence of oxy-
gen. This phenomenon is known as aerobic glycoly-
sis or the ‘‘Warburg effect,’’ and it has been
described as the main metabolic alteration in malig-
nant conversion.
Several biochemical and molecular studies have
described possible mechanisms by which alterations
in glucose metabolism may evolve during cancer
development.11-13 These mechanisms include mito-
chondrial defects and malfunction, adaptation to
hypoxic tumor microenvironment, oncogenic signal-
ing, and an abnormal expression of metabolic
enzymes.11,12
Transketolase (TKT) is a thiamine diphosphate-
dependent enzyme that controls the production of
nucleic acid ribose synthesis in the nonoxidative part
of the pentose phosphate pathway (PPP).14 In cancer,
inhibition of TKT enzyme activity suppresses tumor
growth and metastases.15,16 Three human TKT genes
have been described, TKT, transketolase-like-1
(TKTL1), and transketolase-like-2 (TKTL2). During
evolution, mutations in the TKTL1 gene have led to
the production of tissue-specific transcripts different
in size, which encode an enzymatically active TKT
protein with unusual enzymatic properties and dif-
ferent smaller protein isoforms. TKTL1 enzyme pre-
sents altered substrate specificity and reaction
modus.17 TKTL1 up-regulation in tumors induces an
abnormal oxygen-independent glucose usage and a
lactate-based matrix degradation.15,18 TKTL1 mRNA
expression levels have been found to be up-regulated
in several tumors. Noteworthy is that high levels of
TKTL1 have been reported in gastric, bladder, breast,
lung, prostate, and pancreatic carcinomas.19-23
Furthermore, TKTL1 overexpression is associated
with the aggressiveness of colon, urothelial, ovarian
cancers, and laryngeal squamous cell carcinomas,
and its overexpression correlates with poor patient
survival.16,22,24 Interestingly, the inhibition of TKTL1
induces a reduction in cell proliferation.16,20,23,25
In thyroid cancer, TKTL1 protein expression has
previously been evaluated in follicular, papillary, and
undifferentiated variants, whereas abundant TKTL1
expression has been identified within the cyto-
plasm.16
The aims of the present study were to investigate
the expression of TKTL1 in a series of papillary thyr-
oid carcinomas 1.5 cm and its relation to defined
clinicopathologic features and LN metastases.
MATERIALS AND METHODS
Case Selection
In the present study, we included a group of 256
consecutive patients who had undergone total or
near-total thyroidectomy between January 2001 and
June 2006, with histologic diagnosis of PTC 1.5 cm
in diameter. In 159 cases, clinical signs were present
(clinical or nonincidental carcinomas), whereas in
the remaining 97 cases, the tumor was an incidental
finding (incidental carcinomas) after a lobectomy or
near-total thyroidectomy performed for other dis-
eases (multinodular goiter in 70 cases, toxic multi-
nodular goiter in 10, toxic adenomas in 8, Hashimoto
thyroiditis in 7, and Graves disease in 2). Patients
with incidental carcinomas underwent total thyroid-
ectomy and/or LN dissection within 6-12 months of
diagnosis. Furthermore, laterocervical LNs were dis-
sected when macroscopically involved. Sixty-seven
patients presented regional LN metastases, 56 with
nonincidental and 11 with incidental carcinomas.
This retrospective study was performed in accord-
ance with the rules of the Institutional Review Board
of the Faculty of Medicine (University of Palermo).
Histopathologic Evaluation and Tumor Staging
Tumor specimens were obtained from the archives of
the Department of Human Pathology, University of
Palermo. For each case, all histologic slides were
reviewed by 2 pathologists (V. R. and A. M.), who
were unaware of the clinical data, and histologic
diagnoses were reassessed according to the World
Health Organization histologic classification of thyr-
oid tumors.
All primary tumors included in this study were
classified as classical variants of PTC; tumors with
morphological features of the follicular variant of
PTC were not included. Tumors were staged accord-
ing to the 6th edition of the Cancer Staging Man-
ual,26 where T (extent of the primary tumor) and N
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(regional LN metastases) were determined on the ba-
sis of pathologic data, and M (evidence of distant
metastasis) were based on findings at the first post-
operative 131I-whole-body scan.
Five-mm-thick sections were hematoxylin and
eosin-stained and reassessed with regard to intra-
glandular multifocality, bilaterality, extrathyroidal
extension, vascular invasion, grade of sclerosis (acc-
ording to the amount of fibrous stroma coexisting
with malignant cells), degree of encapsulation
(encapsulated or nonencapsulated), and maximum
diameter of the primary lesion. Sections of LN me-
tastases were reassessed with regard to compartment
involvement, number of involved LNs, and diameter
of the largest metastatic area.
RNA Preparation From Ex Vivo Tissue Specimens
RNA analysis was performed in all cases for which
frozen material was available, which corresponded to
55 PTC tissue fragments (14 cases were with LN me-
tastases and 41 without LN metastasis) and their cor-
responding normal tissue specimens, derived from
uninvolved thyroid glands. Tissue fragments were
obtained from nonincidental tumors nodules >1 cm
by means of careful identification by an experienced
pathologist. These tissue fragments were immediately
stored in RNA (Sigma, Milan, Italy) at 2808C until
their subsequent use. Total RNA from normal and
cancerous thyroid tissues was extracted by using the
RNeasy Mini kit (Qiagen, Hilden, Germany) accord-
ing to manufacturer’s instructions.
Real-Time Polymerase Chain Reaction (PCR) Analysis
RNA was reverse-transcribed by using the Quanti
Tect reverse transcription kit (Qiagen) according to
the manufacturer’s instructions. Real-time PCR was
performed with SYBR Green I dye and the Quanti
Tect SYBR Green PCR kit (Qiagen) and was per-
formed with the ABI PRISM 7900HT Sequence Detec-
tion System (Applied Biosystems, Foster City, Calif)
and conducted by using the following parameters:
508C for 2 minutes, 958C for 10 minutes, 40 cycles at
958C for 15 seconds, and 688C for 1 minute. All
amplification reactions were performed in triplicate,
and the relative quantification of TKTL1 gene expres-
sion was calculated by using the comparative Ct
method (DDCt). Levels of mRNA expression were
expressed after normalization with endogenous-con-
trol b-actin. Data processing and statistical analysis
were performed by using ABI PRISM SDS software v.
2.1 (Applied Biosystems).
Expression differences between tumor and corre-
sponding normal tissue were calculated and are
expressed as fold induction in tumor samples relative
to the corresponding normal sample.
The following primers were used for amplifica-
tion: TKTL1 (TAACACCATGACGCCTACTGC; CATCC
TAACAAGCTTTCGCTG), TKT (TGTGTCCAGTGCATA
GTGG; ACACTTCATATACCCGCCCTAG), TKTL2 (AAA
CTAGGCTTATTTCTAAAAAGTCAAG; GGCTTTGCTTTA
AAAGAAACAG) by referring to Coy et al,15 and b-
actin (CCTAAAAGCCACCCCACTTCTC; ATGCTATCAC
CTCCCCTGTGTG). Primers for TKT, TKTL1, TKTL2,
and b-actin were designed by using PRIMER and
Primer Express (PE Applied Biosystems) software.
Immunohistochemical Study
Immunohistochemical analyses were performed on
5-mm-thick paraffin-embedded sections of thyroid
tumors and LN metastases. Antigen unmasking was
performed in 10 mM sodium citrate (pH 6.0) in a
microwave oven for 1 minute at 450W followed by
5 minutes at 100 W. Endogenous peroxidase was
inhibited with 3% H2O2 for 5 minutes. Endogenous
avidin-biotin was blocked by a biotin blocking sys-
tem (Dako, Glostrup, Denmark) for 10 minutes.
Unspecific staining was blocked with 1% goat serum
for 30 minutes. Sections were subsequently exposed
to mouse anti-TKTL1 (clone JFC12T10; mouse
IgG2b) antibody (15 mg/mL), or isotype-matched
control (Dako) 1 hour at room temperature as pre-
viously described by Coy et al.15 Slides were rinsed in
Tris-buffered saline (TBS), incubated with biotinyl-
ated antimouse immunoglobulins for 30 minutes at
room temperature, and treated with streptavidin-per-
oxidase (LSAB2 Kit, Dako). Staining was revealed by
using 3-amino-9-ethylcarbazole (AEC) substrate
(Dako) and counterstaining with aqueous hematoxy-
lin.
The non-neoplastic tissue present on the same
slides was considered to be a healthy control. More-
over, 20 random specimens, deriving from unin-
volved contralateral thyroid gland in cases with
nonbilateral tumors, were analyzed for TKTL1
expression.
Immunohistochemical Evaluation
For the evaluation of TKTL1 immunoreactions, pri-
mary lesions and metastatic tissues were examined
for evidence of staining. Specimens were analyzed
under a light microscope (Dialux 20 with a plan
403 objective, aperture 0.65, 103 ocular; Leitz, Wet-
zlar, Germany) with an eyepiece graticule to facilitate
cell counting. For each case, a minimum of 103 cells
was counted, and the percentage of tumor cells,
stained with TKTL1 antibody, was regarded as the
labeling index (LI). For multifocal tumors and multi-
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ple LN metastases, evaluations were assessed on dif-
ferent areas of all lesions. Twenty random cases were
evaluated separately by 2 different pathologists
(A. M. and V. R.); because the variation was less than
5%, the first pathologist’s data were used.
Statistical Analyses
Continuous variables were analyzed as mean
value  standard deviation (SD). Rates and propor-
tions were calculated for categorical data. For cate-
gorical variables, differences were analyzed by means
of the w2 test and Fisher exact test when appropriate.
As continuous variables were without normal distri-
bution, we used nonparametric tests, and differences
were analyzed by the Mann-Whitney U-test. Differ-
ences between paired continuous variables were ana-
lyzed by means of the Wilcoxon test. Correlations
among continuous variables were determined by the
use of Spearman test. Group comparisons for quanti-
tative variables were performed by using the Kruskal-
Wallis nonparametric test. P < .05 was considered
statistically significant. All analyses were performed
with Statistical Package for Social Science (SPSS for
Windows, v. 11.0; Chicago, Ill).
RESULTS
The clinicopathologic characteristics of the 256
patients who underwent surgery for the classic vari-
ant of small PTCs (1.5 cm) are shown in Table 1.
Patient age ranged from 17 to 76 years (mean,
42.34  14.48 years), and there was a strong predom-
inance of female patients (82.4%). At presentation,
tumor size was no larger than 1.0 cm in 169 cases
and was between 1.1 and 1.5 cm in 87 cases.
TKTL1 mRNA Levels in Thyroid Carcinoma
TKTL1 mRNA levels were detected by reverse-tran-
scriptase (RT) real-time polymerase chain reaction
(PCR) in 55 PTC fragments and in their correspond-
ing normal tissues and expressed as fold induction of
TKTL1 expression in tumor samples compared with
corresponding normal specimens. TKTL1 mRNA
expression ranged from 0.7 to 134 relative levels. Of
the 55 PTC samples analyzed, 5 samples without LN
metastases showed TKTL1 transcript levels consis-
tently low and with similar levels to their corre-
sponding normal tissues. On the basis of the
presence of LN metastases, we divided specimens in
2 subgroups, 14 cases with LN metastases and 41
without LN metastasis. In the group with LN metas-
tases, TKTL1 mRNA levels ranged from 48.3 to 134
(mean 86.76  25.01). In the group without LN me-
tastases, TKTL1 mRNA levels ranged from 0.7 to 97
(mean, 39.66  27.30); these differences proved to be
significant (P < .001) (Fig. 1).
Moreover, we investigated TKT and TKTL2 mRNA
expression levels in the same samples. Relevant dif-
ferences were not found between normal tissues and
tumor samples in cases with and without LN metas-
tases (data not shown).
Immunohistochemistry of TKTL1
Immunohistochemical staining was performed to
identify the presence of the TKTL1 protein. Consider-
ing primary tumors of the classical variants of PTC,
we have found a predominantly cytoplasmatic stain-
ing with strong positive tumor cells for TKTL1,
whereas the adjacent nonneoplastic tissue, as well as
control samples of uninvolved contralateral gland,
the stromal and follicular cells did not show immu-
noreactivity for TKTL1 (Fig. 2A).
TABLE 1
Clinical and Histopathologic Features of 256 Small PTCs
Parameters No. (%)
Clinical signs
Nonincidental 159 (62)
Incidental 97 (38)
Age, y
<45 136 (53)
45 120 (47)
Sex
Women 211 (82.4)
Men 45 (17.6)
Diameter of primary lesion
1 cm 169 (66)
1.1-1.5 cm 87 (34)
Multifocality
Present 81 (31.6)
Absent 175 (68.4)
Bilaterality
Present 47 (18.4)
Absent 209 (81.6)
Extrathyroidal extension
Present 45 (17.6)
Absent 211 (82.4)
Lymph node metastases
Present 67 (26.8)
Absent 189 (73.2)
Vascular invasion
Present 14 (5.5)
Absent 242 (94.5)
Sclerosis
Present 10 (3.9)
Absent 246 (96.1)
Encapsulation
Present 103 (40.2)
Absent 153 (59.8)
PTC indicates papillary thyroid carcinoma.
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In primary tumors, immunoreactivity for TKTL1
was detected in the majority of cases, ranging from
0% to 95.0% (mean 50.11  27.75%). According to
the results obtained from real-time PCR analysis, all
5 samples that showed TKTL1 transcript levels con-
sistently low and similar to their corresponding nor-
mal tissues also showed very low TKTL1 LI.
Expression of TKTL1 protein was also detected
in LNs metastatic tumor tissues, ranging from 21.9%
to 97.2% (mean, 83.21  13.18%) (Fig. 2B). On exam-
ining the distribution of tumors without LN metasta-
ses (Group I) and with LN metastases (Group II),
significant differences were not found for sex, age,
diameter of primary lesion, and encapsulation; how-
ever, statistical analysis demonstrated a significant
association, apart from clinical signs, between nodal
status and intraglandular multifocality, bilaterality,
extrathyroidal extension, vascular invasion, sclerosis,
and TKTL1 protein expression, as shown in Table 2.
Taking into consideration only cases with LN
metastases (Group II), immunoreactivity for TKTL1
in primary tumors ranged from 19.6% to 95.0%
(mean, 80.48  16.76%); a difference was not
found in TKTL1 protein expression in relation to
primary tumors and their paired LN metastases
(80.48  16.76% vs 83.21  13.18%; P 5 .063) or to
compartment involved (N1a or N1b [78.4  9.47% vs
87.54  7.65%; P 5 .071]), whereas a positive correla-
tion was found between the TKTL1 protein expres-
sion in primary tumors and the number of
metastatic LNs (r 5 0.651; P < .001), as well as
between the TKTL1 protein expression and the diam-
eter of the largest metastatic area in LNs (r 5 0.555;
P < .001).
FIGURE 1. Transketolase-like-1 TKTL1 mRNA expression levels in
papillary thyroid carcinoma (PTC) tissue fragments from nonincidental
nodules >1 cm (14 with lymph-node [LN] metastases and 41 without LN
metastasis). For quantification of TKTL1 transcripts, expression differences
between tumor and corresponding normal tissue were calculated and are
shown as fold induction in tumor samples relative to the corresponding nor-
mal samples. Levels of mRNA expression were expressed after normalization
with endogenous control b-actin. Results are mean values of 3 independent
experiments. Differences were analyzed by the Mann-Whitney U test; statisti-
cal results were considered significant for P < .05.
FIGURE 2. Cytoplasmatic immunostaining for transketolase-like-1 (TKTL1). (A) TKTL1 expression detected in tumor cells but not in the surrounding stromal
cells and in the adjacent nonneoplastic tissue (original magnification 3200). (B) TKTL1 staining in lymph nodal metastatic tissue: positive staining in 79% of
tumor metastatic cells (original magnification 3100).
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Examination of the TKTL1 protein expression in
primary tumors did not show significant differences
for sex, age, tumor diameter, encapsulation, or clini-
cal signs. Statistical analysis, however, demonstrated
a significant association between TKTL1 protein
expression and multifocality, bilaterality, extrathyroi-
dal extension, vascular invasion, and sclerosis (Table
3).
By applying an arbitrary score analysis based on
intraglandular multifocality, bilaterality, tumor extra-
thyroidal extension, vascular invasion, and grade of
sclerosis (range from score 0 5 none of the selected
evaluation criteria present, to score 5 5 all 5 selected
criteria present) and then subdividing the 256
patients, we found that no patients were included in
score 5 and that cases with LN metastases were
found in 8 of 8 (100%) patients with score 4, in 21 of
26 (80.8%) patients with score 3, in 16 of 21 (76.2%)
patients with score 2, in 8 of 45 (17.8%) patients with
score 1, and in 14 of 156 (9%) patients with score 0
(Fig. 3). By analyzing TKTL1 protein expression, we
found that the progressive increase of TKTL1 LI was
significantly associated with the worst score: the
mean value of TKTL1 protein expression was
39.41  25.43% in score 0, 47.94  26.85% in score 1,
69.19  17.57% in score 2, 77.73  12.79% in score 3,
and 92.55  5.96% in score 4, with significant differ-
ences between scores 0 and 2, scores 0 and 3, and
scores 0 and 4. Moreover, all patients in scores 4 and
3 and 19 of 21 (90.5%) in score 2 showed values of
TKTL1 protein expression >50% (Fig. 4).
To identify a TKTL1 LI value of the primary PTC
tumors and to determine whether the probability of
the presence of LN metastases was more likely, we
TABLE 2
Features of 256 Small PTCs in Relation to Lymph Nodes Metastases
Group I Node2 Group II Node1
n=189 n=67
Mean [SD] Mean [SD] P*
Age 40.07 [14.7] 43.25 [13.7] NS
Diameter of primary lesions 10.37 [3.4] 11.04 [3.3] NS
TKTL1 LI 39.34 [22.4] 80.48 [16.7] <.001
No. (%) No. (%) Py
Presence of multifocality 30 (15.9) 51 (76.1) <.001
Presence of bilaterality 5 (2.6) 42 (62.7) <.001
Extrathyroidal extension 19 (10.0) 26 (38.0) <.001
Encapsulation 71 (37.6) 32 (47.7) NS
Vascular invasion 7 (3.7) 7 (10.4) .037
Presence of sclerosis 1 (0.5) 9 (13.4) <.001
Incidental 86 (45.5) 11 (16.4) <.001
PTC indicates papillary thyroid carcinoma; NS, not significant; LI, labeling index.
The distribution of tumors with absence of lymph-node metastases (Group I) and with presence
(Group II), shows a significant association, apart from clinical signs, between node status and TKTL1
protein expression, intraglandular multifocality, bilaterality, extrathyroidal extension, vascular inva-
sion, and sclerosis. For continuous variables, nonparametric tests were used, and differences were
analyzed by the Mann-Whitney U-test. For categorical variables, differences were analyzed by means
of the chi-square test and Fisher exact test, when appropriate. Statistical results were considered sig-
nificant for P values <.05.
*Mann-Whitney test; significant values when P<.05.
yChi-square test; significant values when P< .05.
TABLE 3
Evaluation of TKTL1 Expression in Relation to PTC Characteristics
TKTL1 %
Parameters No. Mean (SD) P*
Multifocality Absent 175 42.68 (25.9)
Present 81 66.16 (24.8) <.001
Bilaterality Absent 209 43.42 (25.9)
Present 47 79.86 (11.6) <.001
Extrathyroidal extension Absent 211 46.22 (26.6)
Present 45 68.37 (25.6) <.001
Vascular invasion Absent 242 48.55 (27.2)
Present 14 77.14 (23.8) <.001
Sclerosis Absent 246 48.82 (27.5)
Present 10 81.83 (7.1) <.001
PTC indicates papillary thyroid carcinoma.
The TKTL1 protein expression in primary tumors was significantly associated with multifocality, bila-
terality, extrathyroidal extension, vascular invasion, and sclerosis. The differences were analyzed by
the Mann-Whitney U-test. Statistical results were considered significant for P values <.05.
*Mann-Whitney test; significant values when P<.05.
FIGURE 3. Subdivision of the 256 patients according to our scoring sys-
tem, based on intraglandular multifocality, bilaterality, tumor extrathyroidal
extension, vascular invasion, and grade of sclerosis [(ranging from a score of
0 (none of the selected evaluation criteria present) to a score of 5 (all 5
selected criteria present)].
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considered an arbitrary value corresponding to the
50th percentile of the TKTL1 LI in Group 0; this
value was 34.5%. Finally, 63 (94%) of the 67 cases
with LN metastases showed a TKTL1 LI >34.5%, and
only 4 (6%) showed a TKTL1 LI 34.5%. The associa-
tion between the presence of LN metastases and
TKTL1 LI >34.5% proved to be highly significant
(odds ratio, 17.32; 95% confidence interval [CI], 6.06-
49.51; P < .001).
DISCUSSION
In this study, we evaluated the clinicopathogic char-
acteristics and the TKTL1 expression of a large series
of small PTCs 1.5 cm in diameter. All of our
patients were treated with total or near-total thyroid-
ectomy, and this allowed us to identify multifocal or
bilateral cancer foci with high accuracy and to maxi-
mize sensitivity of the postoperative 131I-whole-body
scan. We found that approximately 18% of small
PTCs had bilateral foci and/or extrathyroidal exten-
sion, and approximately 27% presented regional LN
metastases. Many studies have highlighted the im-
portance of the presence of initial LN metastases in
papillary cancer. Hay et al27 analyzed 535 microcarci-
nomas and found that local relapse was related to
the presence of metastatic LNs and to the extension
of initial surgery. Baudin et al28 observed that the
most effective predictor of local relapse is the pre-
sence of multiple foci, correlated with the presence
of metastatic LNs at presentation. Our work extends
the correlation of the presence of metastatic LNs at
presentation to intraglandular bilaterality, sclerosis,
extrathyroidal extension, and vascular invasion.
TKTL1 protein has been found overexpressed in
most human carcinomas and has been involved in
tumor progression and invasion.16 In our study,
which compared tumors with their corresponding
normal tissues, we found that TKTL1 transcript
levels were significantly higher in the majority of
cases that we analyzed. This finding demonstrates
that high levels of TKTL1 transcript are a relevant
phenomenon in small PTCs. Moreover, TKTL1
mRNA levels notably increased in primary PTCs
with LN metastases compared with the group with-
out LN metastases.
In primary tumors of the classic variant of PTCs
1.5 cm, we found that immunoreactivity for TKTL1
ranged from 0% to 95.0% and that many tumors
present TKTL1 protein overexpression in accordance
with results obtained from transcript analysis and
with other studies that have involved different types
of epithelial tumor entities. In our own series, the di-
ameter of primary lesions was not associated with
the presence of metastatic LNs at presentation and
with the TKTL1 protein expression, whereas a posi-
tive correlation was found between the diameter of
the largest metastatic area in LNs as well as the
number of metastatic LNs and the TKTL1 protein
expression in primary tumors. These data suggest
that LN metastases at presentation in small PTCs
probably depend on tumor biology and histologic
characteristics more than on the diameter of the pri-
mary tumor.
Moreover, in our own series, the overexpression
of TKTL1 protein was strongly associated with LN
metastases. We also found a significant association
between the TKTL1 expression and multifocality,
bilaterality, extrathyroidal extension, vascular inva-
sion, and sclerosis.
Overexpression of TKTL1 protein may cause an
increase in the nonoxidative part of PPP activity,
leading to the conversion of glucose to ribose
required for nucleic acid synthesis. Moreover, the
nonoxidative part of PPP is responsible for anaerobic
glucose degradation.14 Cancer cells characteristically
acquire the capability of metabolizing high amounts
of glucose by anaerobic degradation, which leads to
production of large amounts of lactate even in the
presence of oxygen.29 This phenomenon is known as
FIGURE 4. Transketolase-like-1 (TKTL1) protein expression in 256 cases of
small papillary thyroid carcinomas (PTCs) subdivided according to our scoring sys-
tem. The progressive increase of TKTL1 LI was significantly associated with the
worst score. The mean value of TKTL1 protein expression was 39.41  25.43%
in score 0, 47.94  26.85% in score 1, 69.19  17.57% in score 2,
77.73  12.79% in score 3, and 92.55  5.96% in score 4, with significant dif-
ferences between scores 0 and 2, scores 0 and 3, and scores 0 and 4 (differences
were analyzed by Kruskal-Wallis test; statistical results were considered signifi-
cant at P<.05). All patients in scores 4 and 3 and 19 of 21 (90.5%) in score 2
showed values of TKTL1 protein expression>50%.
942 CANCER September 1, 2008 / Volume 113 / Number 5
the Warburg effect, and it has been described as the
main metabolic adaptation in malignant altera-
tions.13 Glycolytic phenotype with increased glucose
flux has been almost universally observed in clinical
cancers by the use of positron emission tomography
(PET) along with a glucose analog tracer [fluorodeox-
yglucose (FdG)].29,30
Gatenby et al11,31 proposed an acid-mediated tu-
mor invasion model that provides a simple mecha-
nism for malignant tumor growth. This mechanism
includes promotion of angiogenesis, proteolytic clea-
vage of matrix proteins, and inhibition of immune
response. Nonoxidative glucose degradation in tumor
cells causes the excretion of protons from the tumor
into surrounding normal tissues, thereby subjecting
nontransformed cells adjacent to the tumor to an
extracellular pH significantly lower than normal. The
acid environment leads to the death of neighboring
healthy cells via p53-dependent apoptosis pathways,
as well as by degradation of the interstitial matrix,
loss of intercellular gap junctions, enhanced angio-
genesis, and inhibition of the host-immune response
to tumor antigens. This enables tumor cells to
remain proliferative and to migrate into surrounding
normal tissues, thus producing invasive pheno-
types.32
In our arbitrary scoring system, the progressive
overexpression of TKTL1 was significantly associated
with the worst score. Moreover, in our own series of
the cases with LN metastases, 94% showed a TKTL1
LI >34.5%. Our data suggest that the arbitrary value
of TKTL1 LI >34.5% may be considered a relative
measure of risk for developing LN metastases.
Several studies usually distinguish malignant
tumors from postulated benign tumor counterparts
through the expression of specific molecular mar-
kers. It is widely accepted that a range of benign
papillary lesions mimic papillary carcinoma, but
there is no consensus that these are actually tumors’
benign counterparts.33 Studies of papillary carcinoma
are, thus, deprived of baseline assessment of molecu-
lar-markers expression in the benign counterpart of
malignant tumors. As it is important to provide diag-
nostic tests for distinguishing between clinically
aggressive and clinically indolent forms of tumors,
our findings suggest that the expression level of
TKTL1 may indicate which small PTCs 1.5 cm in
diameter may show aggressive behavior.
In conclusion, to our knowledge, the present
study is the first analysis of TKTL1 protein expression
in primary tumors of the classic variant of PTCs 1.5
cm; thus TKTL1 overexpression in PTC 1.5 cm may
be considered a factor facilitating tumor growth and
progression. Finally, it may also be extremely inter-
esting to investigate an alternative effective way of
inhibiting tumor progression by blocking the genera-
tion of energy and ribose mediated by TKTL1.
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